CD274 and non-small cell lung carcinoma: Recent advancements in immune checkpoint inhibitors have revolutionised the treatment of incurable advanced non-small cell lung cancer (NSCLC) through targets such as the programmed death-ligand 1 (PD-L1) or its receptor, the programmed death-1 (PD-1) pathway.